mubritinib mubritinib mubritinib (tak-165) is a protein kinase inhibitor which was under development by takeda for the treatment of cancer. it completed phase i clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since december 2008. mubritinibclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status in general: uncontrolled identifiers iupac name 1-(4--1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1h-1,2,3-triazole cas number366017-09-6pubchem cid6444692iuphar/bps6011chemspider4948554uniiv734azp9brchemblchembl1614707chemical and physical dataformulac25h23f3n4o2molar mass468.480 g·mol−13d model (jsmol)interactive image smiles fc(f)(f)c1ccc(cc1)\c=c\c2nc(co2)coc3ccc(cc3)ccccn4nncc4 inchi inchi=1s/c25h23f3n4o2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18h,1-3,15,17h2/b13-8+key:ztfbiuxiqyrunt-mdwzmjqesa-n